-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Inhibitor Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2012 to 2023.
- Inhibitor Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$813K, a 7.07% decline year-over-year.
- Inhibitor Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$3.45M, a 34.9% decline year-over-year.
- Inhibitor Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$3.4M, a 418% decline from 2022.
- Inhibitor Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$658K, a 102% decline from 2021.
- Inhibitor Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$325K, a 69.3% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)